BURLINGTON, Mass., Sept. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY, on Wednesday, September 13, 2023, which includes a presentation beginning at 2:55 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$51.60 |
| Daily Change: | -0.33 -0.64 |
| Daily Volume: | 101,085 |
| Market Cap: | US$2.360B |
November 12, 2024 November 04, 2024 October 30, 2024 September 04, 2024 August 12, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
